Stent Types and DAPT Duration
Both drug-eluting stents (DES) and bare-metal stents (BMS) require at least 12 months of dual antiplatelet therapy (DAPT) in acute coronary syndrome patients, but DES used for stable disease can be safely managed with a minimum of 6 months DAPT, while BMS requires only 1 month in stable patients. 1, 2
Understanding the Two Stent Types
Drug-Eluting Stents (DES):
- Stents coated with antiproliferative medications (e.g., sirolimus, paclitaxel, everolimus) that prevent tissue overgrowth
- Dramatically reduce restenosis rates compared to BMS
- Newer-generation DES (everolimus-eluting, biodegradable polymer) have lower thrombosis risk than first-generation devices
- Require longer antiplatelet therapy due to delayed vessel healing
Bare-Metal Stents (BMS) / Mechanical Stents:
- Simple metal scaffolds without drug coating
- Complete endothelialization occurs within 3-4 weeks 3
- Higher restenosis rates but lower late thrombosis risk
- Reserved for patients who cannot tolerate prolonged DAPT (active bleeding, planned surgery, medication nonadherence) 2
DAPT Duration: The Critical Differences
For Acute Coronary Syndrome (ACS) Patients:
Both stent types require ≥12 months DAPT 1, 2
- Aspirin 75-100 mg daily PLUS
- P2Y12 inhibitor (clopidogrel 75 mg, prasugrel 10 mg, or ticagrelor 90 mg twice daily)
- This recommendation applies equally to STEMI and NSTE-ACS patients
For Stable Ischemic Heart Disease:
DES: Minimum 6 months DAPT 2
- The 2016 ACC/AHA guideline reduced this from the previous 12-month requirement
- Based on evidence showing newer-generation DES have equivalent safety with shorter duration 1
BMS: Minimum 1 month DAPT 2
- Shortest required duration due to rapid endothelialization
- Appropriate when patient cannot commit to longer therapy
The Risk-Benefit Tradeoff of Extended DAPT
Extending DAPT beyond 12 months (to 18-48 months) creates a critical balance 1:
Benefits per 1000 patients/year:
- 3 fewer stent thromboses
- 6 fewer myocardial infarctions
Harms per 1000 patients/year:
- 5 more major bleeding events
- Weak evidence suggests possible increased mortality 1
When to Consider Extended DAPT (>12 months):
Favor extension if:
- Prior myocardial infarction (reduces CV death/MI/stroke by 16%, HR 0.84) 1
- Complex lesions or multiple stents
- Low bleeding risk
- Good medication adherence
Avoid extension if:
- High bleeding risk (e.g., requiring anticoagulation, history of major bleeding)
- Prior intracranial hemorrhage
- Planned major surgery
- Poor medication adherence 2
Critical Pitfalls to Avoid
Never discontinue DAPT prematurely in the early period:
- Stopping DAPT within the first month after BMS or first 6 months after DES carries catastrophic stent thrombosis risk 2
- If urgent surgery is needed, weigh bleeding risk against thrombosis risk with cardiology consultation
- At minimum, continue aspirin perioperatively when possible 3
High bleeding risk patients require special consideration:
- Recent evidence (2025) suggests short DAPT (≤3 months) with durable polymer DES offers the best efficacy-safety balance in high bleeding risk patients 4
- Consider stopping P2Y12 inhibitor at 6 months if high bleeding risk develops during treatment 2
Avoid prasugrel in specific populations:
- Absolute contraindication: prior stroke or TIA 2
- Use caution in elderly or low body weight patients
The Bottom Line Algorithm
- Determine clinical presentation: ACS vs. stable disease
- Assess bleeding risk: High vs. standard risk
- Select stent type: DES (preferred for most) vs. BMS (only if DAPT duration is problematic)
- Apply minimum DAPT duration:
- ACS + any stent = 12 months
- Stable + DES = 6 months
- Stable + BMS = 1 month
- Consider extension beyond 12 months only if low bleeding risk AND high ischemic risk (prior MI, complex disease)
The evidence clearly shows that newer-generation DES with appropriately tailored DAPT duration provides superior outcomes for most patients, with BMS reserved as a niche option for those who genuinely cannot receive adequate DAPT duration 1, 2, 5.